sorafenib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702624
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Sorafenib is a first generation type II tyrosine kinase inhibitor with broad specificity for receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to sorafenib-mediated inhibition (Nguyen et al 2017; Linblad et al, 2017;reviewed in Kazi and Roonstrand, 2019).

Literature References
PubMed ID Title Journal Year
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Levis, M, Nguyen, B, Williams, AB, Small, D, Brown, P, Li, L, Young, DJ, Ma, H

Oncotarget 2017
31066629 FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications

Kazi, JU, Rönnstrand, L

Physiol. Rev. 2019
26999641 Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

Vallon-Christersson, J, Puissant, A, Rönnstrand, L, Borg, A, Cordero, E, Levander, F, Stegmaier, K, Kazi, JU, Hemann, MT, Haraldsson, K, Pietras, K, Sun, J, Kabir, NN, Ramos, A, Macaulay, L, Lindblad, O

Oncogene 2016
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!